Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MRANK-119
- Development stage
- Preclinical
- Lead developer
- MindRank
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MRANK-119 is a preclinical-stage small molecule agonist of the gastric inhibitory polypeptide receptor (GIPR), developed by MindRank for the treatment of obesity. Discovered using MindRank's proprietary AI-driven drug discovery platform, the candidate aims to provide a potent and selective oral alternative to existing injectable peptide-based GIP therapies. By activating the GIP receptor, MRANK-119 is designed to modulate energy metabolism and support weight loss.
- Other names
- MRANK-119MRANK119MRANK 119
02
Targets
GIPR (Gastric inhibitory polypeptide receptor)
Beyond the preview
Go deeper on MRANK-119.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MRANK-119.